# Octane and Currus report automated manufacturing transfer for CUR-001 cell therapy

_Published Monday, October 26, 2026 at 8:18 PM EDT · Science · Latest · Tier 2 — Notable_

![Octane and Currus report automated manufacturing transfer for CUR-001 cell therapy — Primary](https://ml-eu.globenewswire.com/media/eeff0d32-8487-4942-ac1c-044868352351/small/updated-logo-png.png)

Octane Biotech and Currus Biologics say they have automated manufacturing of CUR-001, Currus' experimental cell therapy for solid tumours, on Octane's Cocoon platform. The companies say the closed system reduced hands-on operator time and the viral vector required per batch, lowering manufacturing costs.

The process transfer has also been completed at Cell Therapies' Melbourne facility, where CUR-001 will be manufactured for a Phase 1 trial. The treatment combines a patient's modified T cells with a bispecific antibody designed to help activate them against tumours. FDA clearance to begin the trial was announced in September; first patient dosing is expected in early 2027.

## Sources

- [Markets Insider](https://markets.businessinsider.com/news/stocks/octane-biotech-and-currus-biologics-automate-manufacturing-of-cur-001-car-t-cell-therapy-on-the-cocoon-platform-1036667770)

---
Canonical: https://techandbusiness.org/newswire/E5xZqmfreh0V2HhqY5UnYz
Published: 2026-10-27T00:18:05.462Z
Story chronology: 2026-10-26T22:00:00.000Z
Retrieved: 2026-10-27T03:06:01.658Z
Publisher: Tech & Business (techandbusiness.org)